Synthesis and evaluation of biodegradable PCL/PEG nanoparticles for neuroendocrine tumor targeted delivery of somatostatin analog

Dubey, Nazneen; Varshney, Raunak; Shukla, Jaya; Ganeshpurkar, Aditya; Hazari, Puja Panwar; Bandopadhaya, Guru P.; Mishra, Anil K.; Trivedi, Piyush

doi:10.3109/10717544.2012.657718

Cited by 48 publications

(31 citation statements)

References 42 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This could decrease the side effects during the tumor therapy. Solid tumors have leakage microvasculatures (Dubey et al, 2012). Smaller particle size was favorable for passive targeting to the tumor owing to the ''enhanced permeability and retention'' (EPR) effects which resulted in the efficient accumulation in tumor of the LPNs.…”

Section: Discussionmentioning

confidence: 99%

The effective combination therapy against human osteosarcoma: doxorubicin plus curcumin co-encapsulated lipid-coated polymeric nanoparticulate drug delivery system

Wang

Rui

et al. 2016

Drug Delivery

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

The effective combination therapy against human osteosarcoma: doxorubicin plus curcumin co-encapsulated lipid-coated polymeric nanoparticulate drug delivery system

Wang

Rui

et al. 2016

Drug Delivery

View full text Add to dashboard Cite

“…[30] The NP formulated using these polymers have demonstrated excellent stability, increase the drug circulation time, and are capable of solubilizing poorly water soluble drugs while simultaneously delivering multiple drugs. [30][31][32] Incorporation of DTX, EVR, and LY into a NP drug delivery system might overcome the chemoresistance issues while simultaneously targeting the lymphatics. Therefore, we hypothesize that DTX, EVR, and LY loaded PEG-PCL NP with specific size and surface charge density, administered SC, will have preferential uptake and accumulation in the lymphatic system and will exert synergistic antiproliferative effects in clinically relevant melanoma models.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

A three-drug nanoscale drug delivery system designed for preferential lymphatic uptake for the treatment of metastatic melanoma

Doddapaneni

Kyryachenko

Chagani

et al. 2015

Journal of Controlled Release

View full text Add to dashboard Cite

Metastatic Melanoma has a high mortality rate due to lymphatic progression of the disease. Current treatment is surgery followed by radiation and intravenous chemotherapy. However, drawbacks for current chemotherapeutics lie in the fact that they develop resistance and do not achieve therapeutic concentrations in the lymphatic system. We hypothesize that a three-drug nanoscale drug delivery system, tailored for lymphatic uptake, administered subcutaneously, will have decreased drug resistance and therefore offer better therapeutic outcomes. We prepared and characterized nanoparticles (NP) with docetaxel, everolimus, and LY294002 in polyethyleneglycol-block-poly(ε-caprolactone) (PEG-PCL) polymer with different charge distributions by modifying the ratio of anionic and neutral end groups on the PEG block. These NP are similarly sized (~ 48nm), with neutral, partially charged, or fully charged surface. The NP are able to load ~ 2mg/mL of each drug and are stable for 24 h. The NP are assessed for safety and efficacy in two transgenic metastatic melanoma mouse models. All the NP were safe in both models based on general appearance, weight changes, death, and blood biochemical analyses. The partially charged NP are most effective in decreasing the number of melanocytes at both the proximal (sentinel) lymph node (LN) and the distal LN from the injection site. The neutral NP are efficacious at the proximal LN, while the fully charged NP have no effect on either LN. Thus, our data indicates that the NP surface charge and lymphatic efficacy are closely tied to each other and the partially charged NP have the highest potential in treating metastatic melanoma. GRAPHICAL ABSTRACT

show abstract

“…Among these monomers, PEG is suitable to form caprolactone block copolymers because of its hydrophilicity, nontoxicity and absence of antigenicity and immunogenicity (Wei et al, 2009). PCL and its copolymers were utilized to develop nanoparticles containing various drugs (Sinha et al, 2004;Dubey et al, 2012;Pereira Ade et al, 2013;Yin et al, 2013). For instance tamoxifen loaded Poly ethylene oxide-modified poly caprolactone nanoparticles were prepared by Shenoy et.al which demonstrated tumor-selective biodistribution (Shenoy and Amiji, 2005).…”

Section: Introductionmentioning

confidence: 99%

Synthesis, Characterization and in vitro Anti-Tumoral Evaluation of Erlotinib-PCEC Nanoparticles

Barghi¹,

Asgari²,

Barar³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Development of a nanosized polymeric delivery system for erlotinib was the main objective of this research. Materials and Methods: Poly caprolactone-polyethylene glycol-polycaprolactone (PCEC) copolymers with different compositions were synthesized via ring opening polymerization. Formation of triblock copolymers was confirmed by HNMR as well as FT-IR. Erlotinib loaded nanoparticles were prepared by means of synthesized copolymers with solvent displacement method. Results: Physicochemical properties of obtained polymeric nanoparticles were dependent on composition of used copolymers. Size of particles was decreased with decreasing the PCL/PEG molar ratio in used copolymers. Encapsulation efficiency of prepared formulations was declined by decreasing their particle size. Drug release behavior from the prepared nanoparticles exhibited a sustained pattern without a burst release. From the release profiles, it can be found that erlotinib release rate from polymeric nanoparticles is decreased by increase of CL/PEG molar ratio of prepared block copolymers. Based on MTT assay results, cell growth inhibition of erlotinib has a dose and time dependent pattern. After 72 hours of exposure, the 50% inhibitory concentration (IC50) of erlotinib hydrochloride was appeared to be 14.8 μM. Conclusions: From the obtained results, it can be concluded that the prepared PCEC nanoparticles in this study might have the potential to be considered as delivery system for erlotinib.

show abstract

Synthesis and evaluation of biodegradable PCL/PEG nanoparticles for neuroendocrine tumor targeted delivery of somatostatin analog

Cited by 48 publications

References 42 publications

The effective combination therapy against human osteosarcoma: doxorubicin plus curcumin co-encapsulated lipid-coated polymeric nanoparticulate drug delivery system

The effective combination therapy against human osteosarcoma: doxorubicin plus curcumin co-encapsulated lipid-coated polymeric nanoparticulate drug delivery system

A three-drug nanoscale drug delivery system designed for preferential lymphatic uptake for the treatment of metastatic melanoma

Synthesis, Characterization and in vitro Anti-Tumoral Evaluation of Erlotinib-PCEC Nanoparticles

Contact Info

Product

Resources

About